Thrombotic events after discontinuing dabigatran: rebound or resumption?
| Autor: | Sisira Jayathissa, Katie M Thorne, Stephen Dee |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.drug_mechanism_of_action
Factor Xa Inhibitor beta-Alanine Pharmacology Dabigatran chemistry.chemical_compound Thrombin Recurrence medicine Humans Aged 80 and over Rivaroxaban business.industry Anticoagulants Thrombosis General Medicine Heparin Middle Aged medicine.disease chemistry Benzimidazoles business medicine.drug |
| Zdroj: | BMJ. 345:e4469-e4469 |
| ISSN: | 1756-1833 |
| Popis: | The REMODEL trial has suggested that stopping dabigatran does not produce a rebound thrombotic effect.1 2 However, others have raised the possibility of this.3 Such rebound pro-thrombotic activity and clusters of thrombotic events have been reported with heparin and older anti-thrombotic drugs, and concerns are now being expressed about the newer anticoagulants, including the factor Xa inhibitor, rivaroxaban, and oral direct thrombin … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|